My research focuses on new types of nanoparticle agents for multiple types of imaging such as 1H and 19F magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), single photon emission CT (SPECT), bioluminescence, ultrasound, optoacoustics and fluorescence, simultaneously.
The particles contain liquid perfluorocarbons with a metal chelate in a polymer matrix, resulting in a unique structure that we are actively studying through different types of NMR and even Small Angle Neutron Scattering (SANS), among others.
We are also developing the nanoparticles to comprehensively monitor modern personalised medicine, such as cell therapies, targeted therapies and theranostics. I am involved with all aspects of this work, including label development and formulation for human (GMP) and preclinical use, cell handling and labeling, in vivo animal models, imaging, development for clinical application and upscaling production. The work is inherently multidisciplinary, and I work with immunologists, chemists, physicists and physicians (primarily radiologists and cardiologists), with a clinical trial in melanoma patients in progress.
I am also actively involved in commercialisation of this work, with several patents filed already, and a spin-off set up (Cenya Imaging B.V.). Finally, I play a very active role in science policy and dissemination, through my role as current incoming Chair at the Young Academy of Europe.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.